Immutep Ltd

NASDAQ:IMMPUnited States

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Contact Information

Headquarters

Plaza Building, L 12 95 Pitt StSYDNEY, NSW, Australia NSW 2000

Phone

---

Fax

---

Executives

Independent Non-Executive Chairman of the Board

Russell Howard

Chief Executive Officer, Executive Director

Marc Voigt

Independent Non-Executive Deputy Chairman of the Board

Peter Meyers

Chief Operating Officer, General Counsel, Joint Company Secretary

Deanne Miller

Chief Scientific Officer, Executive Director

Frederic Triebel